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How did the study come about?
Although less well recognized than in the West, cardiovascular
disease (CVD) is the leading cause of disease in Asia. This is
despite known differences in the distribution of risk factors for
CVD in Asia, compared with Europe and North America, such
as lower average total cholesterol and body mass index (BMI).
The nature of CVD also tends to be different in Asia, where
there are more strokes than coronary heart disease (CHD)
events, and strokes are more often haemorrhagic than
ischaemic, compared with the West.
By 1999 the knowledge gap in Asia was a clear impediment
to progress in treating and preventing CVD in the continent.
Most of the existing studies from Asia were of small size or
short duration and, thus, could not provide reliable information
as to the way risk factors, well-researched in the West, act upon
CVD in Asia. A notable exception was the Eastern Stroke and
CHD Collaborative Project,1 which had studied the effects of
diastolic blood pressure and total cholesterol on the risk of
stroke and coronary disease in China and Japan. This was the
starting point for the Asia Pacific Cohort Studies Collaboration
(APCSC),2 which extended the scope of the Eastern Project in
several important ways. APCSC covers a wider geographical
area, including studies from Australia and New Zealand
(ANZ), which provide a ‘Western’ comparison group, as
well as increasing numbers for certain pooled analyses. It
uses individual participant, rather than summary, data, which
allows for more flexible analyses. Also, it collects data on
several risk factors for CVD, not just blood pressure and total
cholesterol, and records all deaths, including those due to
non-cardiovascular causes.
Initial funding was provided by the New Zealand Health
Research Council and the Australian National Health and
Medical Research Council (NHMRC). Twin Secretariats for
APCSC were established at the Clinical Trials Research Unit at
the University of Auckland, New Zealand and The George
Institute for International Health at the University of Sydney,
Australia. In later years, Pfizer Inc. of New York provided two
substantial unrestricted educational grants to APCSC. Current
funding is a mixture of pharmaceutical industry funding
(Pfizer), peer reviewed research council funding (NHMRC;
through a programme grant), and university funding (a Uni-
versity of Sydney cancer research award). The Secretariat and
database are now solely housed within The George Institute.
What does it cover?
The primary aims of APCSC are to determine the age-specific,
sex-specific, and region-specific (Asia and ANZ) associations of
major cardiovascular risk factors with
 stroke (fatal and non-fatal, ischaemic and haemorrhagic),
 CHD (fatal and non-fatal),
 total CVD.
Secondary outcomes are
 all-cause mortality and
 other major causes of death (e.g. cancer).
The primary analytical method is to use Cox proportional
hazard regression models, adjusted for age and stratified by
study (and where appropriate, sex) to calculate hazard ratios
and confidence intervals. Continuous variables are adjusted for
regression dilution error.2
Who is in the sample?
Studies are eligible for inclusion in APCSC if they are based in
the Asia Pacific region, use a cohort study design, and have at
least 5000 person-years of follow-up. Individuals within each
study are included if they have recordings, at baseline, of date
of birth (or age), sex and blood pressure, and have vital status
known at the end of follow-up, together with date of death
(or the age at death) where applicable. Cohorts selected on the
basis of a positive disease history, or diagnosis, are excluded.
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Studies were identified by a range of methods, including
searches of electronic databases (MEDLINE and EMBASE),
scrutiny of abstracts and proceedings of meetings, and by
personal enquiry among collaborators and colleagues. For each
identified eligible study, the principal investigators (PIs) were
invited to participate. Figure 1 shows the distribution of studies
included in the APCSC database at the time of the third
datalock, in April 2006 (previous datalocks were in 2000 and
2003). Study names, and names of PIs, are given in the
acknowledgements; this includes two studies that have agreed
to join APCSC but have yet to qualify according to the entry
criteria. The studies in Figure 1 are the only ones included in
the remainder of this article.
How often have they been followed-up?
APCSC studies are free to contribute whatever data they like to
the Collaboration. Of the 44 studies, 28 have only provided
baseline data; 16 have additionally provided data on one repeat
enumeration and six have contributed more than one repeat
set of measurements, up to a maximum of seven repeats. The
median follow-up is 6.7 years and the longest follow-up of any
individual, not yet deceased, is 36 years.
What has been measured?
Baseline
As the primary outcomes in this collaboration are cardio-
vascular, the baseline risk factors collected are all the
well-established risk factors for CVD. Table 1 gives a list of
these risk factors, with numbers of individual data points.
Methods used to measure risk factors varied; for instance 13
studies gave glucose from fasting samples and six from
non-fasting. Wherever possible, methods and classifications
were standardized. Several studies provided further variables,
such as social classifications and ethnicity, but these were not
consistently reported and are not amenable for analyses.
Repeat values
Values from repeat sampling have been provided for many
continuous measures: the number of individuals with repeat
measures for blood pressure 5 48 113, total cholesterol (n 5
21 575), HDL-cholesterol (n 5 7629), triglycerides (n 5 10 734),
BMI (n 5 21305), and glucose (n 5 4396). The median time to
resampling was 3 years. From these data, regression dilution
coefficients were calculated2 using the MacMahon-Peto non-
parametric method.2,3 These were 1.9 for systolic blood
pressure, 2.1 for diastolic blood pressure, 1.7 for total
cholesterol, 1.9 for HDL-cholesterol, 1.8 for triglycerides, 1.2
for BMI, and 1.6 for glucose.
Outcomes
Data on deaths were available for every study participant,
according to the entry criteria. Figure 2 shows the underlying
cause of death (taken as the sole cause of death in APCSC),
where available. Different studies used different methods of
coding, such as various incarnations of the International
Figure 1 Map showing studies in the Asia Pacific Cohort Studies Collaboration
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Classification of Diseases (ICD). Indeed, studies may have used
different ICD codes in different periods. Some studies used
rather broader classifications than others; hence, the prolifera-
tion of unknown classifications at lower levels in Figure 2.
Cause of death was unknown, or unreported, in 1021 (4%) of
cases. Non-fatal events were requested for stroke (provided by
19 cohorts) and CHD (16 cohorts). Non-fatal stroke events by
subtype were reported by 17 cohorts. Methods for obtaining
information on non-fatal events differed across the studies but
was mainly due to either self-report in repeat questionnaires or
by review of medical records.
What has it found? Key findings and
publications
At the time of writing, 21 papers have been published, or are
about to be published, from APCSC, while more than a dozen
further papers are in various stages of processing. The latter,
unpublished research, includes reports on cancer outcomes.
Published papers have shown that all the major cardiovascular
risk factors work at least as strongly in Eastern as in Western
populations.4 Given the enormous size of the populations
concerned, this result is important, since it implies that
Western research and treatment regimens have relevance in
Asia. Policies for prevention must, however, be specific to the
populations, given the cultural differences even within Asia.
Blood pressure seems to be a key risk factor for stroke and CHD
in Asia, with hazard ratios, after adjusting for other risk factors,
that are considerably greater than those in ANZ.4 APCSC has
shown that blood pressure,5 cholesterol,6 and glucose7 have
log-linear relationships with CHD; results that often only
become clear with large datasets. Most risk factors for CVD
have been found to have greater hazard ratios in younger age
groups and to work similarly between the sexes. An exception
to the latter is diabetes; in this case APCSC data have helped
to provide conclusive evidence of higher coronary relative risks
in women.8
What are the main strengths and
weaknesses?
The great strengths of APCSC include the large amount of raw
data and the strong collaboration, involving several ethnic
groups. Day-to-day management is undertaken by a dedicated
group in Sydney and the project is overseen by an Executive
Committee, an elected representative group from across the
countries involved. Three meetings of the entire collaboration
have been held so far, as well as extra meetings of the
Executive Committee. Some of the current funding has been
used to hold a training workshop in Korea, with further
funding earmarked for two similar workshops in China and
Taiwan. Research publications are published in the name of the
Collaboration, with writing committees that include represen-
tatives from across the geographical spread of APCSC. Language
difficulties in China have been addressed by translating key
documents, such as the regular APCSC newsletters, while five
of the publications have been translated and submitted for
re-publication in a Chinese medical journal. An APCSC website
has been set up, with many special features available only to
the collaborators. All these factors have helped maintain such
a diverse collaboration for several years.
The main weaknesses of APCSC relate to non-
standardization of data collection methods. All the cohorts
were begun before the Collaboration was initiated, without a
common protocol. This has the potential to introduce bias
when analysing continuous exposure variables, particularly
when comparing subgroups that may be unequally distributed
Table 1 Numbers of observations for each variable, age range, and
percentage female, by region, Asia Pacific Cohort Studies
Collaboration
Asia ANZ All
Total 513 022 87 421 600 443
Blood pressure
Systolic 513 022 87 421 600 443
Diastolic 513 022 87 421 600 443
Heart rate 58 629 54 052 112 681
Tobacco
Current cigarette smoking 478 875 87 283 566 158
Other tobacco smoking 28 669 24 628 53 297
Years of smoking cigarettes 96 790 10 190 106 980
Alcohol
Current drinking 471 158 82 697 553 855
Lipids
Total cholesterol 295 868 84 615 380 483
Triglycerides 79 886 18 588 98 474
High density lipoprotein
cholesterol
56 161 24 162 80 323
Low density lipoprotein
cholesterol
10 717 2896 13 613
Glucose 214 819 50 526 265 345
Anthropometric
Hip 8270 29 013 37 283
Waist 8306 25 548 33 854
Weight 344 448 86 467 430 915
Height 424 736 86 064 510 800
BMI 343 498 86 035 429 533
Medical history
Coronary disease 111 966 87 092 199 058
Stroke 114 104 81 378 195 482
Diabetes 100 240 82 336 182 576
Medications
Cholesterol-reducing 13 902 19 592 33 494
Blood pressure-reducing 59 964 69 587 129 551
Ethnicity 42 069 67 682 109 751
Education level 235 709 74 634 310 343
Occupation 197 676 13 587 211 263
% Female
a
35.7 45.3 35.7
Age range
a
20–107 20–104 20–107
a
Age and sex were recorded for everyone.
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amongst the studies and makes analysis of categorical variables
crude or impractical. Outcome variables have similar issues; for
example, stroke subtypes are not always reported, are verified
using different techniques in different studies (or at different
times within the same study), and either do or do not include
non-fatal events. Pooling studies with outcome data of such
different quality and quantity requires assumptions, which may
not always be well-founded.
Can I get hold of the data? Where can
I find out more?
The data are held by the Sydney Secretariat and are not
available for use by outsiders, including the sponsors. Members
of the Collaboration who wish to work on the data have to do
so in Sydney, having obtained prior approval from the
Executive Committee. Further details on APCSC, including a
full list of publications, are available from the Website: www.
apcsc.info.
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Figure 2 Fatal events, by cause, recorded in the Asia Pacific Cohort Studies Collaboration
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